Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

NCX-4016 reported to decrease platelet activation in patients with type 2 diabetes

March 3, 2005

Positive phase I findings for CYT006-AngQb for hypertension

March 2, 2005

FDA extends PDUFA action date for nebivolol NDA

March 2, 2005

Curacyte to merge with IBFB Pharma

March 1, 2005

Alteon suspends enrollment in alagebrium trials

March 1, 2005

Genzyme initiates phase II gene transfer study in peripheral arterial disease

Feb. 28, 2005

Corgentech to discuss registration strategy for edifoligide with FDA

Feb. 28, 2005

First HERG channel activator discovered

Feb. 28, 2005

Triple inhibitors tested for the treatment of cardiovascular and renal diseases / News in Context

Feb. 25, 2005

Atacand approved for treatment of heart failure

Feb. 24, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Recombinant vaccine inhibits HBV-associated HCC growth
BioWorld Science
Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....